JapanBiotech & Genomic Medicine▲
Caion Signs Joint Research Agreement with FRONTEO for AI Drug Discovery
Caion has entered into a joint research agreement with FRONTEO regarding AI drug discovery. Additionally, CAPITA will record a special gain in the second quarter of the fiscal year ending March 2027 due to the sale of idle land. JMHD has revised down its consolidated earnings forecast for the fiscal year ending July 2026. Nexera has received a milestone payment of $86 million from Centessa based on progress in late-stage development. DWTi has decided on a domestic development plan for its glaucoma treatment agent H-1337. Blangista has seen additional share acquisition by SBINM LLC in connection with the strengthening of capital ties with SBI.
About megatrends
Biotech & Genomic Medicine › AI Drug Discovery Technology
2158.JP · Technology · Positive FRONTEO signed a joint research agreement with Caion for AI drug discovery.
4565.JP · Capital · Positive Nexera received an $86 million milestone payment from Centessa based on late-stage development progress.
4576.JP · Technology · Positive DWTi decided on a domestic development plan for its glaucoma treatment agent H-1337.
CPI.LSE · Capital · Positive CAPITA will record a special gain in Q2 FY ending March 2027 from the sale of idle land.
6176.JP · Capital · Neutral SBINM LLC acquired additional Brangista shares in connection with strengthening capital ties with SBI; effect on Brangista is unclear.
CNTA · Demand · Positive Centessa paid an $86 million milestone to Nexera based on progress in late-stage development, indicating advancement of its pipeline.